<DOC>
	<DOCNO>NCT01220154</DOCNO>
	<brief_summary>Phase I study evaluate intraperitoneal carboplatin along weekly intravenous paclitaxel bevacizumab order establish tolerable dose define toxicity regimen previously untreated patient advance ovarian carcinoma .</brief_summary>
	<brief_title>Study Intraperitoneal Carboplatin With IV Paclitaxel Bevacizumab Untreated Ovarian Cancer</brief_title>
	<detailed_description>Phase I study primary objective determine maximum tolerate dose intraperitoneal carboplatin intravenous weekly paclitaxel give combination intravenous bevacizumab second two cycle treatment patient chemo-naive epithelial ovarian , primary peritoneal fallopian tube cancer . The maximum tolerate dose defined high dose 1 6 evaluable patient experience dose limit toxicity second two cycle treatment . Secondary objective determine response rate estimate progression free survival overall survival class patient .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histology diagnose epithelial ovarian , primary peritoneal , fallopian tube ( Stage II , III IV ) either optimal suboptimal initial surgery . All patient must appropriate surgery ovarian , peritoneal , fallopian tube carcinoma tissue available histologic evaluation Histologic epithelial cell type eligible : serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarinoma , undifferentiated carcinoma , clear cell adenocarcinoma , mixed epithelial carcinoma , transitional cell carcinoma , malignant brenner tumor , adenocarcinoma NOS . GOG ( Gynecologic Oncology Group ) performance status 0,1,2 Entered within 12 week recent surgery perform diagnosis . Patients must adequate bone marrow function , renal function , hepatic function , neurologic function , blood coagulation parameter within normal limit Sign approve consent form . Patients receive prior treatment initial surgery Patients receive prior radiotherapy portion abdominal cavity pelvis Patients acute hepatitis active infection Patients active bleed Patients unstable angina Patients history invasive malignancy exception nonmelanoma skin cancer localize breast cancer . Patients receive target therapy hormonal therapy management ovarian cancer . Patients synchronous primary endometrial cancer . Patients epithelial tumor low malignant potential Serious non heal wound , ulcer bone fracture . Patients history evidence CNS ( central nervous system disease ) Patients 18 year old . Patients receive prior therapy antiVEGF ( vascular endothelial growth factor ) drug , bevacizumab Patients history allergic reaction polysorbate 80 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ovarian</keyword>
	<keyword>cancer</keyword>
	<keyword>fallopian tube</keyword>
	<keyword>peritoneal</keyword>
	<keyword>intraperitoneal</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>carboplatin</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>chemo-naive</keyword>
</DOC>